An agency of the European Union Guidance on the Submission of Clinical Reports intended for Publication in Accordance with Policy 0070 Principles Industry.

Slides:



Advertisements
Similar presentations
PubMed Central Mahyar Ahmadpour-B. Kowsar Publicatin Corp. Kowsar Editorial Meeting 1 September 19th, 2013 Tehran, Iran.
Advertisements

The Application for Renewal Accreditation: Electronic Submissions.
©2014 Factorytalk Co., Ltd. Proprietary and Confidential eCTD Specification 17 July 2014.
What is so good about Archie and RevMan 5
Submitting Book Chapters via Manuscript Central A Short Guide for Wiley-VCH Authors.
ESPON 2013 Programme Info Day on Calls and Partner Café Brussels, 10 May 2012 How to apply: Application Form and Eligibility A Decade of Territorial.
Letter of intent By to predefined format (Word file, see guidelines) Chair Scientific Committee Coordination EO To all members of.
PCT-SAFE and e-Services developments Webinar September 7/
IAEA International Atomic Energy Agency. IAEA Outline Learning Objectives The Mission Report Purpose and objectives What is not needed? Evolution of the.
DMF Procedures and Communication between API, FP Manufacturers and Regulatory Authorities Jean-Louis ROBERT National Health Laboratory L – 1011 LUXEMBOURG.
Tracking & Review Attaching Documents, Proposal Review, and Submission Office of Grant & Contract Services 17 January 2012.
ROAD ACCIDENT FUND VENDOR BRIEFING SESSION RAF/ 2013 /00009 Date: 27 May 2013 Time: 11:00.
An agency of the European Union Presented by: Emer Cooke and Truus Janse-de Hoog Update on Transparency Progress report from HMA/EMA TF on Transparency.
CONTENTS 1.Work done in JUNE (22nd-30th)‏ i) Stage 1:Concept proposal acceptance module upload (Slide 2nd)‏ 2. Work done in JULY a) Stage 1: Improvised.
Rev.04/2015© 2015 PLEASE NOTE: The Application Review Module (ARM) is a system that is designed as a shared service and is maintained by the Grants Centers.
IRES: an update on the revision process Vladimir Markhonko United Nations Statistics Division The 4 th meeting of the Oslo Group on energy statistics Ottawa,
FP6 IT System 1 ELECTRONIC PROPOSAL SUBMISSION SYSTEM.
The Basics Craig Johnson Grant Administrator Department of Medicine Instructor.
IAEA International Atomic Energy Agency Methodology and Responsibilities for Periodic Safety Review for Research Reactors William Kennedy Research Reactor.
CTD Dossier Preparation K. Srikantha Reddy Sr
Due Process – ISSAIs and INTOSAI GOVs Roberto José Domínguez Moro Superior Audit Office of Mexico INTOSAI Working Group on Public Debt June 14, 2010.
Scope of the Journal The International Journal of Sports Medicine (IJSM) provides a forum for the publication of papers dealing with basic or applied information.
1 Addendum FALL 2004 RFP Detailed Instructions for Bidder Registration and Proposal Submission ENTERGY SERVICES, INC. November 2004.
Reporting. CONTENT Types of project assessment reports Questionnaires – follow-up of researchers Declaration on Conformity Amendments SESAM and reporting.
January 2009: PRS Template Presentation PRS for Music Code of Conduct.
Consumers, Health, Agriculture and Food Executive Agency 3rd Health Programme The Electronic Submission System (JA 2015) Georgios MARGETIDIS.
“EMA policy on publication of Clinical Data” 27/11/2014SFdS - Journée Annuelle du groupe Biopharmacie & Santé.
A little bit of history Directive 65/65/EC founds European pharmaceutical legislation but excludes medicines used for research purposes from.
Swissmedic Swiss Agency for Therapeutic Products Hallerstrasse 7 CH-3000 Bern Workshop 2 - Paragraph 13 TPA 2nd Follow-up Information.
ICORD 2006 Kerstin Westermark Md, PhD, Assoc. prof. COMP Chairperson.
An agency of the European Union Guidance on the anonymisation of clinical reports for the purpose of publication in accordance with policy 0070 Industry.
Main topics Who are we at EMA and what is our regulatory experience in Parkinson’s disease (PD) Initiatives available at EMA to stimulate and support.
POST APPROVAL CHANGE MANAGEMENT PROTOCOLS IN THE EUROPEAN UNION
Paediatric Medicine: The Paediatric Investigation Plan
Dr Pascale POUKENS-RENWART Scientific Officer
Periodic Safety Update Reports (PSUR)
Use case review update 10 September 2018 Agenda item 4.0
ROAD ACCIDENT FUND VENDOR BRIEFING SESSION RAF/ 2013 /00009
Content of Tender Dossier - Instructions to Tenderers - Tenders
ELECTRONIC PROPOSAL SUBMISSION SYSTEM
EU CT form - update 11 September 2018 Agenda item 4.0
EMA policy on publication of clinical data – Update on implementation
Grid Code What is the Standard Modification Process? Panel
Industry stakeholder follow-up meeting, 23 June 2015 Agenda topic 5
To login into the InfoReady system:
Agenda 5.11 General Regulations
PREPARATION OF DOCUMENTATION FOR CONSTITUENT BODIES MEETINGS
eSubmission Web Client – XML delivery files
CONDITIONAL MARKETING AUTHORISATION
Union referral procedures
eSubmission PSUR XML Delivery File
ICANN62 GAC Capacity Building
EMA Working Groups on Committees' Operational Preparedness
Gibraltar Financial Services Commission
eSubmission Web Client XML delivery file – new functionality
Industry Best Practice Guide: Schedule 2, Part 1 Paragraph 2 Completing RAD 2: Step by Step Guide This document is to be used as a guidance on how to complete.
EU SUBMISSION BY Haripriya & Revathy.
REPORTING and PAYMENT (in practice)
FP7 SCIENTIFIC NEGOTIATIONS
Information session SCIENTIFIC NEGOTIATIONS Call FP7-ENV-2013-two-stage "Environment (including climate change)" Brussels 22/05/2013 José M. Jiménez.
IRRS REFRESHER TRAINING Lecture 4
The partnership principle in the implementation of the CSF funds ___ Elements for a European Code of Conduct.
WHAT TO EXPECT: A CROWN CORPORATION’S GUIDE TO A SPECIAL EXAMINATION
NEF Negotiation forms IT tool to support Negotiation (Participant Portal) Call FP7-ENV-2013-WATER-INNO-DEMO.
Changing the Reference Member State (RMS)
1st meeting of the CIOMS Working Group XI, 19 April 2018
BPR AS Review Programme
An introduction to EMA’s support for medicines development
Sustainable Mobility & Automotive industry Unit
EU Regulatory Pathways for ATMPs: Standard, Accelerated and Adaptive Pathways to Marketing Authorisation  Giulia Detela, Anthony Lodge  Molecular Therapy.
Presentation transcript:

An agency of the European Union Guidance on the Submission of Clinical Reports intended for Publication in Accordance with Policy 0070 Principles Industry stakeholder follow-up meeting, 23 June 2015 Agenda topic 3 Presented by Frances Nuttall Senior Policy Adviser

The following will be detailed with respect to the submission requirements for clinical reports provided by Applicants for publication in line with Phase 1 of Policy 0070: 1. Packages for submission to the Agency 2. Submission and publication timelines 3. Redaction Proposal version requirements 4. Notifications to Applicants to submit their Redaction Proposal version 5. Final Redacted version requirements 6. Support for Applicants Guidance on the Submission of Clinical Reports intended for Publication in Accordance with Policy Contents

Packages for Submission Applicants must submit two packages, a Redaction Proposal package and Final Redaction package, to the Agency. The following are the required components of the Redaction Proposal package: All redaction proposal versions of the clinical reports A cover letter with a declaration confirming that the clinical reports submitted for scientific evaluation are the same as that submitted for publication, with the exception of redactions A completed justification table (detailing CCI redactions only) in Word format for each document. Where there are disagreements, concomitant outcomes must be addressed in all corresponding documents An anonymisation report and that of the Final Redaction package: All final redacted versions of the clinical reports A cover letter Guidance on the Submission of Clinical Reports intended for Publication in Accordance with Policy 00702

Submission & Publication Timelines: MAAs and Line Extension Applications The timelines 1 for the provision of the Redaction Proposal and Final Redacted version of the clinical reports and their publication by the Agency are as follows for MAAs and line extension applications: Submission by the Applicant Redaction Proposal: Day 181 to Day 220 (≤ 30 days pre-opinion and ≤ 10 days post-opinion) Publication by the Agency Final Redacted Version: ≤ 60 days of the issuance of EC Decision 1 (in calendar days) Guidance on the Submission of Clinical Reports intended for Publication in Accordance with Policy 00703

Submission & Publication Timelines: Extensions of Indications and Withdrawals Submission by the Applicant Redaction Proposal for Extensions of Indications: ≤ 30 days pre-opinion and ≤ 10 days post- opinion Redaction Proposal for Withdrawn Applications: ≤ 30 days post-receipt of the withdrawal letter Publication by the Agency Final Redacted Version for Extension of Indication: ≤ 60 days of the issuance of EC Decision Final Redacted Version for Withdrawn Applications: ≤ 150 days post-notification of the withdrawal to the Agency by the Applicant Guidance on the Submission of Clinical Reports intended for Publication in Accordance with Policy 00704

Redaction Proposal Applicants must prepare a Redaction Proposal version of their clinical reports for publication. The preparation of these documents must adhere to the following requirements: Documents must be submitted in PDF format The text proposed for redaction should be clearly identified as such (i.e. marked) and the text itself should be legible (read-through) It should be possible to easily (with minimal intervention) render the proposed redactions permanent or to remove the redaction It should be possible to select one or more marked proposed redactions for comment, redaction or deletion. Editing individual proposed redactions should be possible for all parties and clearly tracked. For the upload of the Redaction Proposal via the Gateway, a separate sequence with submission type ‘Supplemental Information’ under module 1 of the eCTD must be created (using eCTD operator ‘new’). Guidance on the Submission of Clinical Reports intended for Publication in Accordance with Policy 00705

Notifications to Applicants: MAAs and Line Extension Applications Applicants will receive 3 advanced warnings of their requirement to submit a Redaction Proposal at the following time points for MAAs and line extension applications: 1.With the validation letter 2.With the day 180 list of outstanding issues 3.With the CHMP opinion letter In each case, the notification will be issued within the letter sent to the Applicant for the relevant stage of the scientific review process Guidance on the Submission of Clinical Reports intended for Publication in Accordance with Policy 00706

Notifications to Applicants: Extensions of Indications and Withdrawals Applicants will also receive 3 advanced warnings of their requirement to submit a Redaction Proposal at the following time points for extensions of indications: 1.With the validation letter 2.With the Request for Supplementary Information 3.With the CHMP opinion letter and 2 advanced warnings at the following time points for withdrawn applications: 1.With the validation letter 2.With the withdrawal letter to the Applicant Guidance on the Submission of Clinical Reports intended for Publication in Accordance with Policy 00707

Final Redacted Version (1/2) Applicants must produce, using a redaction tool, a Final Redacted Version of the clinical reports prior to publication. Documents submitted to the Agency for publication with the final redactions must adhere to the following requirements: Documents must be submitted in PDF format The unredacted text only must be text-searchable. Redacted text and the redaction box should neither be searchable nor subject to editing Redactions must be clearly visible (typically using a black rectangle) Should any redaction codes be agreed these should be visible and irremovable together with the redacted text The Final Redacted Version of documents in colour should also be in colour Guidance on the Submission of Clinical Reports intended for Publication in Accordance with Policy 00708

Final Redacted Version (2/2) Applicants must create a separate sequence with submission type ‘Supplemental Information’ under module 1 of the eCTD (using eCTD operator ‘new’) for the Final Redacted Version This sequence must be separate from that created for the Redaction Proposal Applicants must also upload a cover letter with the Final Redacted Version In the cover letter Applicants must also confirm that what is submitted as the Final Redacted Version is the full set of documents for publication Guidance on the Submission of Clinical Reports intended for Publication in Accordance with Policy 00709

Support for Applicants The EMA will be offering the following support to Applicants to assist with the redaction of clinical reports for publication: A user license for a redaction tool for use by SMEs A helpdesk to support SMEs with redactions and the consultation process Guidance on the Submission of Clinical Reports intended for Publication in Accordance with Policy

Thank you for your attention European Medicines Agency 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0) Facsimile +44 (0) Send a question via our website Follow us